journal article·2023-09-12Open access

Stability Criterion for the Assembly of Core–Shell Lipid–Polymer–Nucleic Acid Nanoparticles

Juan L. Paris, Ricardo Gaspar, Filipe Coelho, Pieter A. A. De Beule, Bruno F. B. Silva

ACS Nano· Volume 17· Issue 17

Abstract

High Resolution Image Download MS PowerPoint Slide Hybrid core–shell lipid–polycation–nucleic acid nanoparticles (LPNPs) provide unique delivery strategies for nonviral gene therapeutics. Since LPNPs consist of multiple components, involving different pairwise interactions between them, they are challenging to characterize and understand. Here, we propose a method based on fluorescence cross-correlation spectroscopy to elucidate the association between the three LPNP components. Through this lens, we demonstrate that cationic lipid shells (liposomes) do not displace polycations or DNA from the polycation–DNA cores (polyplexes). Hence, polyplexes and liposomes must be oppositely charged to associate into LPNPs. Furthermore, we identify the liposome:polyplex number ratio ( ρ N ), which was hitherto an intangible quantity, as the primary parameter predicting stable LPNPs. We establish that ρ N ≥ 1 ensures that every polyplex is enveloped by a liposome, thus avoiding coexisting oppositely charged species prone to aggregation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · RNA and protein synthesis mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

International Iberian Nanotechnology Laboratory, Braga, 4715-330, Portugal

Funding

Fundaci?n Ram?n Areces · European Regional Development Fund · Funda??o para a Ci?ncia e a Tecnologia

References (35)

Show source-provided references
1. 10.1038/s41565-019-0591-y10.1038/s41565-019-0591-y ↗
2. 10.1126/science.abm082910.1126/science.abm0829 ↗
3. 10.1038/nature1830010.1038/nature18300 ↗
4. 10.1038/nature2300310.1038/nature23003 ↗
5. 10.1056/NEJMoa210745410.1056/NEJMoa2107454 ↗
6. 10.1126/science.281.5373.7810.1126/science.281.5373.78 ↗
7. 10.1073/pnas.172054211510.1073/pnas.1720542115 ↗
8. 10.1021/acsnano.8b0151610.1021/acsnano.8b01516 ↗
9. 10.1038/s41565-021-01030-y10.1038/s41565-021-01030-y ↗
10. 10.3390/pharmaceutics1309136510.3390/pharmaceutics13091365 ↗
11. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
12. 10.1021/jm200237p10.1021/jm200237p ↗
13. 10.1016/j.jconrel.2014.04.02310.1016/j.jconrel.2014.04.023 ↗
14. 10.1016/B978-0-12-800148-6.00005-510.1016/B978-0-12-800148-6.00005-5 ↗
15. 10.1002/ange.20160845010.1002/ange.201608450 ↗
16. 10.1016/j.biomaterials.2017.02.01910.1016/j.biomaterials.2017.02.019 ↗
17. 10.1038/nm.435610.1038/nm.4356 ↗
18. 10.1038/s41551-018-0284-010.1038/s41551-018-0284-0 ↗
19. 10.1002/adhm.20190170510.1002/adhm.201901705 ↗
20. 10.1021/cr500679310.1021/cr5006793 ↗
21. 10.1021/acsnano.8b0096610.1021/acsnano.8b00966 ↗
22. 10.1016/j.cis.2013.08.00810.1016/j.cis.2013.08.008 ↗
23. 10.3390/cells909203410.3390/cells9092034 ↗
24. 10.1038/nprot.2007.41010.1038/nprot.2007.410 ↗
25. 10.1073/pnas.200844711710.1073/pnas.2008447117 ↗
26. 10.1002/jbio.20200020010.1002/jbio.202000200 ↗
27. 10.1038/nnano.2012.21210.1038/nnano.2012.212 ↗
28. 10.1002/adma.20170675910.1002/adma.201706759 ↗
29. 10.1021/jp404812a10.1021/jp404812a ↗
30. 10.1021/nl303581q10.1021/nl303581q ↗
31. 10.1039/C5CC06767G10.1039/C5CC06767G ↗
32. 10.1021/acs.chemmater.6b0003010.1021/acs.chemmater.6b00030 ↗
33. 10.1073/pnas.223568810010.1073/pnas.2235688100 ↗
34. 10.1002/cphc.20110080110.1002/cphc.201100801 ↗
35. 10.1002/cphc.20180057610.1002/cphc.201800576 ↗